Holen Sie sich die Stockscreener-App
12.36
0.61%
-0.085
Schlusskurs vom Vortag:
$12.28
Offen:
$12.2
24-Stunden-Volumen:
808
Relative Volume:
0.04
Marktkapitalisierung:
$95.16M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+3.74%
1M Leistung:
-6.73%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$12.20
$12.20
1-Wochen-Bereich:
$12.00
$12.53
52-Wochen-Spanne:
$10.00
$23.76
Jatt Ii Acquisition Corp Stock (JATT) Company Profile
Firmenname
Jatt Ii Acquisition Corp
Sektor
Branche
Telefon
201-688-0364
Adresse
C/O APPLEBY GLOBAL SERVICES (CAYMAN) LTD, GEORGE TOWN
Compare JATT vs LION, XXI, UMAC, CCXI, DMII
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JATT
Jatt Ii Acquisition Corp
|
12.20 | 95.75M | 0 | 0 | 0 | 0.00 |
LION
Lionsgate Studios Corp
|
11.02 | 3.32B | 2.63B | -175.60M | 11.40M | -0.7173 |
XXI
Twenty One Capital Inc
|
5.735 | 3.30B | 0 | 4.35M | 456.40K | 0.3397 |
UMAC
Unusual Machines Inc
|
24.96 | 1.30B | 17.25M | -5.64M | -40.16M | -0.3337 |
CCXI
Churchill Capital Corp Xi
|
13.56 | 757.52M | 0 | 0 | 0 | 0.0647 |
DMII
Drugs Made In America Acquisition Ii Corp
|
10.21 | 647.51M | 0 | 8.58M | -1.11M | 0.134 |
Jatt Ii Acquisition Corp Aktie (JATT) Neueste Nachrichten
JATTJatt II Acquisition Corp Volatility & Greeks - Finviz
JATT Acquisition Corp Class A (JATT) Peer Comparison – Compare with Others - Value Research
JATT III Acquisition Corp Announces Closing of $69,000,000 Initial Public Offering - Moomoo
JATT III raised $69 million without choosing a business to buy - Stock Titan
JATT mastermind launches latest biotech-focused SPAC in $60M IPO - Fierce Biotech
Jatt III Acquisition Corp Announces Pricing Of $60 Million IPO - TradingView
JATT II Acquisition: Guggenheim Securities, LLC Is Acting as Sole Book-Running Manager >JTTT - Moomoo
Balyasny Asset Management L.P. Initiates Position in JATT II Acq - GuruFocus
ADAR1 Capital Management (JATT) discloses 5.4% beneficial stake in JATT II - Stock Titan
JATT II Acquisition Corp. (JATT) investors file update showing 0% stake - Stock Titan
JATT II Acquisition Corp (JATT) reports 6.23% stake held by Great Point - Stock Titan
Atika Capital (JATT) discloses 5.1% beneficial stake in JATT II Acquisition Corp. - Stock Titan
Balyasny Asset Management (JATT) discloses 6.23% holding in JATT II common stock - Stock Titan
Janus Henderson Group (JATT) discloses 6.2% beneficial stake in JATT II - Stock Titan
JATT II Acquisition Corp. (JATT) plans Talawar merger backed by $225M PIPE - Stock Titan
JATT II Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
VSCTF Stock Price and Chart — OTC:VSCTF - TradingView
COPL|Copley Acquisition Corp|Price:10.480|Chg%:+0.010 - TradingKey
JATT II Acquisition Corp Revenue Breakdown – NASDAQ:JATT - TradingView
FACT|FACT II Acquisition Corp|Price:10.660|Chg%:+0.010 - TradingKey
BBCQ|Bleichroeder Acquisition II Units|Price:10.170| - TradingKey
MACI|Melar Acquisition Corp I|Price:10.910|Chg%:+0.010 - TradingKey
ASPC|A SPAC III Acquisition Corp|Price:10.542|Chg%:-0.098 - TradingKey
SPEG|Silver Pegasus Acquisition Corp|Price:10.300| - TradingKey
WTG|Wintergreen Acquisition Corp|Price:10.490|Chg%:+0.020 - TradingKey
FSHP|Flag Ship Acquisition Corp|Price:11.110| - TradingKey
JATT|JATT II Acquisition Ord Shs|Price:13.240|Chg%:-0.540 - TradingKey
ENHA|A Paradise Acquisition Ord Shs Class A|Price:2.650|Chg%:+0.020 - TradingKey
Talawar Therapeutics Appoints Steve Migausky as Chief Legal and Administrative Officer - PR Newswire
Jatt Ventures Ii L.p. Net Worth (2026) - GuruFocus
Biotech-Focused Hedge Funds Back Talawar’s Fast Moving SPAC Merger - Institutional Investor
JATT II Acquisition (JATT) sponsor forfeits 225,000 shares after over-allotment expiry - Stock Titan
JATT II Acquisition Corp. (JATT) sponsor forfeits 225,000 Ordinary Shares - Stock Titan
Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases - AOL.com
Talawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger - Yahoo Finance
Price to book forward of JATT II Acquisition Corp – NASDAQ:JATT - TradingView
Talawar (NASDAQ: TLWR) to Merge with JATT II; $285M Expected - Stock Titan
Price to sales forward of JATT II Acquisition Corp – NASDAQ:JATT - TradingView
Price to earnings forward of JATT II Acquisition Corp – NASDAQ:JATT - TradingView
Talawar Therapeutics and JATT II Announce $285M Merger to Advance Bispecific Antibody for Atopic Dermatitis - Minichart
Talawar–JATT II deal includes $225M PIPE (NASDAQ: JATT) - Stock Titan
Biotech SPAC deal gets it to Nasdaq; AstraZeneca Phase 3 win in children's bone disease - Endpoints News
Talawar Tx launches as publicly traded biotech - The Pharma Letter
Enterprise value to revenue forward of JATT II Acquisition Corp – NASDAQ:JATT - TradingView
Enterprise value to EBIT forward of JATT II Acquisition Corp – NASDAQ:JATT - TradingView
JATT II Acquisition to Merge With Talawar Tx; JATT to Become Subsidiary in SPAC Deal - TradingView
Talawar, JATT II (Nasdaq: JATT) unveil $225M PIPE-backed biotech merger - Stock Titan
Talawar Therapeutics To Go Public Through A SPAC Deal With JATT II Acquisition - Pulse 2.0
JATT II Acquisition, Talawar Therapeutics announce combination agreement - TipRanks
Press Release: Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases - Moomoo
Talawar Tx Inc. entered into a definitive business combination agreement to acquire JATT II Acquisition Corp. from JATT Ventures II L.P. in a reverse merger transaction. - marketscreener.com
Finanzdaten der Jatt Ii Acquisition Corp-Aktie (JATT)
Es liegen keine Finanzdaten für Jatt Ii Acquisition Corp (JATT) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.66%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):